F. Fioritoni

发表

Circulating endothelial progenitor cells and residual in vivo thromboxane biosynthesis in low-dose aspirin-treated polycythemia vera patients.

G. Lessiani, F. Santilli, G. Davı̀, 2008, Blood.

vera patients thromboxane biosynthesis in low-dose aspirin-treated polycythemia Circulating endothelial progenitor cells and residual in vivo

F. Santilli, G. Davı̀, M. Romano, 2008 .

First report of vaginal infection caused by Enterococcus raffinosus.

F. D’Antonio, G. Di Bonaventura, D. D’Antonio, 2008, Journal of medical microbiology.

Carfilzomib induction, consolidation, and maintenance with or without autologous stem-cell transplantation in patients with newly diagnosed multiple myeloma: pre-planned cytogenetic subgroup analysis of the randomised, phase 2 FORTE trial.

V. Pavone, M. Boccadoro, R. Mina, 2022, The Lancet. Oncology.

Isolation of multidrug-resistant Enterobacter cloacae and comparison among clavulanate-tazobactam and sulbactam-synergy by using a double-disk synergy test

D. D’Antonio, V. Savini, C. Catavitello, 2008 .

Ulcer Infection by ESβL-Producing Proteus mirabilis: A Case Report

G. Di Bonaventura, D. D’Antonio, V. Savini, 2008, The international journal of lower extremity wounds.

Soluble CD40 ligand and endothelial dysfunction in aspirin‐treated polycythaemia vera patients

G. Lessiani, F. Santilli, G. Davı̀, 2009, British journal of haematology.

P36 BELANTAMAB MAFODOTIN IN PATIENTS WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA WHO HAVE RECEIVED AT LEAST ONE PROTEASOME INHIBITOR, ONE IMMUNOMODULATORY AGENT AND ONE ANTI-CD38 MONOCLONAL ANTIBODY: A RETRO-PROSPECTIVE ITALIAN OBSERVATIONAL STUDY

M. Boccadoro, L. Baldini, A. Cuneo, 2022, HemaSphere.

S300: HEALTH-RELATED QUALITY OF LIFE IN TRANSPLANT-INELIGIBLE REAL-LIFE MULTIPLE MYELOMA PATIENTS TREATED WITH BORTEZOMIB-MELPHALAN-PREDNISONE (VMP) VS. LENALIDOMIDE-DEXAMETHASONE (RD)

M. Boccadoro, A. Larocca, S. Bringhen, 2022, HemaSphere.

Impact of minimal residual disease standardised assessment by FDG-PET/CT in transplant-eligible patients with newly diagnosed multiple myeloma enrolled in the imaging sub-study of the FORTE trial

M. Boccadoro, C. Nanni, S. Fanti, 2023, EClinicalMedicine.

Allogeneic stem cell transplantation in multiple myeloma: is there still a place?

F. Fioritoni, Mauro Di Ianni, Carmine Liberatore, 2024, Frontiers in Oncology.